Secukinumab is effective for the management of moderate-to-severe psoriasis and has a good safety profile.

The long-term effectiveness and safety of Secukinumab to relieve psoriasis in real life was examined in a 240-week multicenter retrospective study.

Data from adult patients who had Secukinumab treatment for a minimum of 192 weeks and up to 240 weeks were analyzed. Clinical data was gathered, incorporating concomitant comorbidities and previous therapies. Dermatology Life Quality Index (DLQI), Body Surface Area (BSA), and Psoriasis Area and Severity Index (PASI) were used to determine effectiveness at the time Secukinumab was started as well as at weeks 4, 12, 24, 48, 96, 144, 192, and 240.

There were 275 subjects (174 men), with a mean age of 50.80 ± 14.78 years; 71.6% had comorbidities, 24.4% of them had psoriatic arthritis, and 29.8% of them had an unusual localization. From week 4, DLQI, BSA, and PASI all showed considerable improvement.

Between weeks 24 and 240, 62–90% claimed that their psoriasis had no impact on their quality of life (DLQI 0-1), 83–93% experienced mildly impacted BSA (BSA ≤3), and 97–10% of patients had mild PASI scores (≤10). Adverse events were experienced by only 2.6% of patients. No participant discontinued therapy during the study period. 

When taken for extended periods of time, Secukinumab is a highly efficacious and safe drug for psoriasis patients, with minimal incidence of adverse events.